Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics?

  title={Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics?},
  author={Daniel Tarsy and Ross J. Baldessarini},
  journal={Movement disorders : official journal of the Movement Disorder Society},
  volume={21 5},
Second-generation antipsychotic drugs (APDs), including aripiprazole, clozapine, olanzapine, risperidone, quetiapine, and ziprasidone dominate outpatient and inpatient clinical practice, having largely displaced the older neuroleptics. Modern APDs have relatively low risk for acute extrapyramidal syndromes characteristic of older neuroleptics, particularly acute dystonia and Parkinsonism, with variable risks of akathisia and the rare neuroleptic malignant syndrome. Anticipated reduction in risk… CONTINUE READING